Department of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
Anticancer Res. 2010 Feb;30(2):575-9.
gammadelta T-cells have recently attracted considerable attention in the development of novel cancer immunotherapy, and several different approaches have been designed and employed in clinical trials.
A patient with lung metastasis after radical nephrectomy for renal cell carcinoma had six cycles of adoptive immunotherapy using autologous in vitro-activated gammadelta T-cells followed by low-dose interleukin-2 and zoledronic acid intravenous infusion. Complete remission was achieved which has been maintained for 2 years without any additional treatment. Immunological analysis demonstrated a high level of interferon-gamma four hours through one day following the transfer and peripheral blood gammadelta T-cells increased 10-fold from the baseline value, 7 days after the transfer. No serious adverse events were observed.
Adoptive immunotherapy using gammadelta T-cells was shown here to be clinically beneficial and safe, and may become a therapeutic option for patients with advanced RCC.
γδ T 细胞在新型癌症免疫疗法的发展中最近引起了相当大的关注，并且已经设计并在临床试验中采用了几种不同的方法。
一名患者因肾细胞癌行根治性肾切除术切除后发生肺转移，接受了六轮自体体外激活的γδ T 细胞过继免疫治疗，随后进行低剂量白细胞介素-2 和唑来膦酸静脉输注。完全缓解已维持 2 年，无需任何额外治疗。免疫分析显示，转移后 4 小时至 1 天内干扰素-γ水平升高，转移后 7 天外周血 γδ T 细胞比基线值增加 10 倍。未观察到严重不良事件。
本研究表明，使用γδ T 细胞的过继免疫疗法具有临床获益和安全性，可能成为晚期 RCC 患者的治疗选择。
